These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 26824643)

  • 1. Mimicking of Arginine by Functionalized N(ω)-Carbamoylated Arginine As a New Broadly Applicable Approach to Labeled Bioactive Peptides: High Affinity Angiotensin, Neuropeptide Y, Neuropeptide FF, and Neurotensin Receptor Ligands As Examples.
    Keller M; Kuhn KK; Einsiedel J; Hübner H; Biselli S; Mollereau C; Wifling D; Svobodová J; Bernhardt G; Cabrele C; Vanderheyden PM; Gmeiner P; Buschauer A
    J Med Chem; 2016 Mar; 59(5):1925-45. PubMed ID: 26824643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On the terminal homologation of physiologically active peptides as a means of increasing stability in human serum--neurotensin, opiorphin, B27-KK10 epitope, NPY.
    Seebach D; Lukaszuk A; Patora-Komisarska K; Podwysocka D; Gardiner J; Ebert MO; Reubi JC; Cescato R; Waser B; Gmeiner P; Hübner H; Rougeot C
    Chem Biodivers; 2011 May; 8(5):711-39. PubMed ID: 21560227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and evaluation of novel multimeric neurotensin(8-13) analogs.
    Hultsch C; Pawelke B; Bergmann R; Wuest F
    Bioorg Med Chem; 2006 Sep; 14(17):5913-20. PubMed ID: 16735124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of the guanidine-acylguanidine bioisosteric approach to argininamide-type NPY Y₂ receptor antagonists.
    Pluym N; Brennauer A; Keller M; Ziemek R; Pop N; Bernhardt G; Buschauer A
    ChemMedChem; 2011 Sep; 6(9):1727-38. PubMed ID: 21692185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel bioactive and stable neurotensin peptide analogues capable of delivering radiopharmaceuticals and molecular beacons to tumors.
    Achilefu S; Srinivasan A; Schmidt MA; Jimenez HN; Bugaj JE; Erion JL
    J Med Chem; 2003 Jul; 46(15):3403-11. PubMed ID: 12852770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enantioselective syntheses of alpha-Fmoc-Pbf-[2-(13)C]-L-arginine and Fmoc-[1,3-(13)C2]-L-proline and Incorporation into the neurotensin receptor 1 ligand, NT(8-13).
    Song C; Tapaneeyakorn S; Murphy AC; Butts C; Watts A; Willis CL
    J Org Chem; 2009 Dec; 74(23):8980-7. PubMed ID: 19883062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuropeptides: metabolism to bioactive fragments and the pharmacology of their receptors.
    Hallberg M
    Med Res Rev; 2015 May; 35(3):464-519. PubMed ID: 24894913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and human neurotensin receptor binding activities of neurotensin(8-13) analogues containing position 8 alpha-azido-N-alkylated derivatives of ornithine, lysine, and homolysine.
    Lundquist JT; Dix TA
    J Med Chem; 1999 Nov; 42(23):4914-8. PubMed ID: 10579853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of N-terminal modifications on neurotensin(8-13) analogues correlates peptide stability but not binding affinity with in vivo efficacy.
    Orwig KS; Lassetter MR; Hadden MK; Dix TA
    J Med Chem; 2009 Apr; 52(7):1803-13. PubMed ID: 19290594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-activity analysis of N-acetyl [Leu(28,31)] NPY 24-36: a potent neuropeptide Y Y(2) receptor agonist.
    Smith-White MA; Potter EK
    Neuropeptides; 1999 Dec; 33(6):526-33. PubMed ID: 10657536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis of neurotensin(9-13) analogues exhibiting enhanced human neurotensin receptor binding affinities.
    Lundquist JT; Büllesbach EE; Dix TA
    Bioorg Med Chem Lett; 2000 Mar; 10(5):453-5. PubMed ID: 10743946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-activity relationships of neuropeptide FF: role of C-terminal regions.
    Mazarguil H; Gouardères C; Tafani JA; Marcus D; Kotani M; Mollereau C; Roumy M; Zajac JM
    Peptides; 2001 Sep; 22(9):1471-8. PubMed ID: 11514031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of lactam-bridged neurotensin analogues adjusting psi(Pro10) close to the experimentally derived bioactive conformation of NT(8-13).
    Bittermann H; Einsiedel J; Hübner H; Gmeiner P
    J Med Chem; 2004 Oct; 47(22):5587-90. PubMed ID: 15481995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Alkyne-functionalized Arginine for Solid-Phase Synthesis Enabling "Bioorthogonal" Peptide Conjugation.
    Spinnler K; von Krüchten L; Konieczny A; Schindler L; Bernhardt G; Keller M
    ACS Med Chem Lett; 2020 Mar; 11(3):334-339. PubMed ID: 32184966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide backbone modifications on the C-terminal hexapeptide of neurotensin.
    Einsiedel J; Hübner H; Hervet M; Härterich S; Koschatzky S; Gmeiner P
    Bioorg Med Chem Lett; 2008 Mar; 18(6):2013-8. PubMed ID: 18276136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreatic polypeptide-fold peptide receptors and angiotensin II-induced renal vasoconstriction.
    Dubinion JH; Mi Z; Zhu C; Gao L; Jackson EK
    Hypertension; 2006 Mar; 47(3):545-51. PubMed ID: 16365188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Introduction of lipidization-cationization motifs affords systemically bioavailable neuropeptide Y and neurotensin analogs with anticonvulsant activities.
    Green BR; White KL; McDougle DR; Zhang L; Klein B; Scholl EA; Pruess TH; White HS; Bulaj G
    J Pept Sci; 2010 Sep; 16(9):486-95. PubMed ID: 20645434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N(ω)-Carbamoylation of the Argininamide Moiety: An Avenue to Insurmountable NPY Y1 Receptor Antagonists and a Radiolabeled Selective High-Affinity Molecular Tool ([(3)H]UR-MK299) with Extended Residence Time.
    Keller M; Weiss S; Hutzler C; Kuhn KK; Mollereau C; Dukorn S; Schindler L; Bernhardt G; König B; Buschauer A
    J Med Chem; 2015 Nov; 58(22):8834-49. PubMed ID: 26466164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluorescence- and luminescence-based methods for the determination of affinity and activity of neuropeptide Y2 receptor ligands.
    Ziemek R; Brennauer A; Schneider E; Cabrele C; Beck-Sickinger AG; Bernhardt G; Buschauer A
    Eur J Pharmacol; 2006 Dec; 551(1-3):10-8. PubMed ID: 17027743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of the neurotensin receptor 1 in the behavioral effects of two neurotensin agonists, NT-2 and NT69L: lack of hypothermic, antinociceptive and antipsychotic actions in receptor knockout mice.
    Mechanic JA; Sutton JE; Berson AE; Wu X; Kwan J; Schreiber R; Pang Z; Button DC
    Eur Neuropsychopharmacol; 2009 Jul; 19(7):466-75. PubMed ID: 19223157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.